What if a familiar medication could offer a new way to help young people through difficult periods of depression?
Sometimes, getting through a difficult season is the first step toward feeling well again. That possibility is at the heart of emerging research into ketamine, a medication that has been used in hospitals for decades and is now being studied for its potential to provide rapid relief from severe depression and suicidal thoughts.
For adolescents, whose emotional lives and circumstances can change dramatically as they grow, the possibility of faster relief is especially meaningful. A treatment that helps someone feel better sooner might give other forms of care, including psychotherapy, supportive relationships, and conventional medications, more time to take effect.
Recent studies are beginning to explore whether ketamine could play that role.
New Research Offers an Intriguing Finding
In April 2026, researchers published a pilot study in BMC Psychiatry examining intravenous ketamine in adolescents ages 12 to 17 who arrived at emergency departments experiencing moderate to severe suicidal thoughts.
Twenty teenagers participated. Half received a single dose of ketamine, while the other half received a placebo. All subsequently received standard emergency psychiatric care.
One finding stood out: None of the ten teenagers who received ketamine required psychiatric hospitalization during their initial emergency department visit, compared with four of the ten teenagers in the placebo group.
The study was too small to establish that ketamine was responsible for this difference, and it did not demonstrate a statistically significant reduction in suicidal thoughts compared with placebo.
Follow-up results were also mixed. Seven teenagers in the ketamine group returned to the emergency department for mental health concerns within 30 days, compared with one in the placebo group. Differences in the participants' initial depression severity may have influenced these outcomes.
The findings are preliminary, but they demonstrate that researchers can study rapid-acting treatments in adolescent emergency care. Other research is adding to the picture.
A larger study involving 147 adolescents examined esketamine, a closely related medication administered as a nasal spray. Esketamine is marketed under the brand name Spravato by Janssen Pharmaceuticals, a Johnson & Johnson company, and has been FDA-approved for certain forms of depression in adults since 2019.
In the adolescent study, participants also received comprehensive psychiatric care, including hospitalization, antidepressants, and psychotherapy. Researchers found significantly greater improvement in depressive symptoms within 24 hours among adolescents receiving certain esketamine doses compared with the control treatment. Although Spravato is not FDA-approved for adolescents, these findings offer an encouraging direction for further research.
Another small randomized emergency department trial involving 29 adolescents did not find significantly greater improvements with intravenous ketamine than placebo. Taken together, these studies offer an early picture of both the possibilities and the unanswered questions. Ketamine has not been established as a treatment that prevents suicide in adolescents, but researchers are learning more about its potential to provide faster relief.
An Old Medicine With a New Possibility
One of the most interesting aspects of this research is that ketamine occupies an unusual position in pediatric medicine. For decades, physicians have administered ketamine to children undergoing surgery and painful medical procedures. Yet its potential use for adolescent depression remains relatively unexplored.
A 2026 systematic review examined 20 studies involving 58,752 children who received intravenous ketamine for procedural sedation.
Serious adverse events, as defined by the review, occurred in approximately 0.33% of cases. No deaths or permanent adverse outcomes were reported in the included studies. That's a substantial body of experience with ketamine's short-term physical safety when administered by trained medical professionals.
The doses being investigated for depression are generally lower than those used to induce anesthesia, although different dosing schedules and treatment purposes mean their effects cannot be assumed to be identical. This history doesn't establish that ketamine is safe or effective as a psychiatric treatment. Repeated administration, long-term effects, and its impact on the developing brain still require study. But it does mean we're investigating a new application for a medication with an extensive record of pediatric use.
That existing experience deserves a prominent place in the conversation about ketamine's psychiatric potential.
Understanding Medical Caution
In 2018, the American Academy of Child and Adolescent Psychiatry urged extreme caution regarding ketamine and esketamine use in young people, citing the limited controlled pediatric research available at that time.
There's an important difference between a treatment that has been demonstrated to cause harm and one whose potential benefits and risks haven't yet been adequately studied. Ketamine has known risks, including dissociation, temporary increases in blood pressure, sedation, and potential misuse. Its longer-term effects with repeated psychiatric use in adolescents remain uncertain.
Those concerns deserve attention, just as the potential for meaningful relief deserves investigation. Research involving children requires additional protections, and appropriately so. These safeguards can make clinical studies more challenging, but recent trials demonstrate that meaningful research is possible. Responsible medical caution and the pursuit of better treatments can work together. In fact, progress depends on both.
Creating a Window for Healing
What interests me most about this research is the possibility of helping someone through a particularly difficult period. We often think about mental health treatment in terms of long-term recovery, and rightly so. But there is also tremendous value in helping someone find relief in the present.
Conventional antidepressants may take several weeks to achieve their full therapeutic effects. Ketamine's antidepressant effects can emerge within hours in some adults, and researchers are investigating whether adolescents might experience similar benefits.
Imagine if a young person experiencing severe depression could begin to feel some relief sooner. That improvement might create a therapeutic window, a period when they can more fully participate in therapy, reconnect with supportive relationships, and engage with the care that will help sustain their recovery. It might also provide valuable time for a newly prescribed conventional medication to begin working.
The adolescent research hasn't yet established that ketamine can reliably create this window, but the possibility is worth pursuing. A rapid-acting treatment would be one part of a larger plan, supported by appropriate psychiatric care and follow-up. Sometimes getting through a difficult season is the beginning of a much larger recovery.
Looking Ahead With Hope
Ketamine may eventually become an additional treatment option for some adolescents experiencing severe depression. Larger studies will help determine who might benefit, how treatment should be delivered, and how long its effects might last.
For families interested in learning more, the growing research offers an opportunity to have informed conversations with qualified medical professionals about emerging treatments and clinical trials.
The most encouraging part of this work is the possibility that we may one day have more ways to help young people find relief when they need it.
Sometimes, what someone needs most is enough breathing room for healing to begin.
A difficult season in a young person's life doesn't have to define their future. Sometimes the most important thing we can offer is the care and support that helps them move through it, with all the possibilities of their life still ahead of them.
If a young person is experiencing suicidal thoughts and needs immediate support, call or text 988. If they are in immediate danger, seek emergency medical care.
References and Further Reading
1. Schlegelmilch, M., et al. (2026). Single Dose IV Ketamine for Adolescent Suicidal Ideation in the Emergency Department: A Pilot Randomized Trial. BMC Psychiatry.
2. Kosik-Gonzalez, C., et al. (2026). Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study. Journal of the American Academy of Child & Adolescent Psychiatry, 65(1), 42–55.
3. Vayngortin, T., et al. (2026). Intravenous Ketamine for Depressed and Suicidal Adolescents in the Emergency Department: A Randomized Double-Blind Trial. Western Journal of Emergency Medicine.
4. Green, S. M., & Roback, M. G. (2026). Systematic Review of Pediatric Ketamine in Emergency Department Procedural Sedation: Frequency and Predictors of Adverse Events. Annals of Emergency Medicine.
5. American Academy of Child and Adolescent Psychiatry. (2018). AACAP Psychopharmacology Committee Statement on Ketamine.